

SATURDAY, NOVEMBER 2, 2019

Morning Sessions	
8:00am-8:05am	Welcome by symposium chairs & co-chairs
<i>Clonal hematopoiesis and myelodysplasia</i>	
8:05am-8:25am	<p>Is CHIP the real precursor of AML in adults?</p> <p><i>Speaker: Peter van Galen, MD Harvard Medical School</i></p>
8:30am-8:50am	<p>Proteome Disbalance in Aged Hematopoiesis</p> <p><i>Speaker: Andre Catic, PhD Baylor College of Medicine</i></p>
8:55am- 9:15am	<p>Epigenetic malignant modification, is this reversible?</p> <p><i>Speaker: Guillermo Garcia Manero, MD The University of Texas, MD Anderson Cancer Center</i></p>
9:20am-9:40am	<p>Uncovering the inflammasome- a new light for MDS therapy.</p> <p><i>Speaker: Eric Padron, MD Lee Moffit Cancer Center</i></p>
9:45am-10:05am	<p>Case based lecture on- What is beyond erythropoiesis stimulating agent in LR-MDS</p> <p><i>Speaker: Gustavo Rivero, MD Baylor College of Medicine</i></p>
10:05am-10:10am	BREAK
10:10am-10:30am	<p>Case based lecture on- high-risk MDS what is beyond epigenetic therapy failure?</p> <p><i>Speaker: Thomas Prebet, MD, PhD Yale University</i></p>
<i>Acute myelogenous Leukemia</i>	
10:35am-11:00am	<p>Do we have a consensus for MRD definition in AML?</p> <p><i>Speaker: Christopher S. Hourigan, MD, DPhil National Heart Lung and Blood, NIH</i></p>

11:05am-11:25am	MRD guided therapy for favorable ELN risk <i>Speaker: Francesco Buccisano, MD</i> <i>Tor Vergata University of Rome, Italy</i>
11:30am-11:50am	MRD guided therapy for unfavorable AML ENL-risk <i>Speaker: Christian Thiede, MD</i> <i>University Hospital Carl Gustav Carus</i>
11:50am-12:45am	POSTER EXHIBITS • POSTER PRESENTATION
Afternoon Sessions	
12:45pm-1:15pm	What have we learned after 1 year of IDH inhibition? <i>Speaker: Courtney DiNardo, MD</i> <i>MD Anderson Cancer Center Hospital</i>
1:20pm-1:50pm	Mechanism of resistance to FLT3 inhibition- How to improve responses? <i>Speaker: Mark Levis, MD, PhD</i> <i>The Sidney Kimmel Comprehensive Cancer Center-Johns Hopkins University</i>
1:55pm-2:15pm	Elderly AML - how to best treat? <i>Speaker: Hetty Carraway, MD, BA, FACP</i> <i>Cleveland Clinic Lerner College of Medicine, Western Reserve University</i>
2:20pm-2:40pm	BREAK
2:45pm-3:15pm	Panel discussion - Let's work on a good MRD definition!!! NGS vs flow cytometry, or both? For MRD <i>Christopher S. Hourigan, MD, DPhil</i> <i>Guillermo Garcia Manero, MD</i> <i>Hetty Carraway, MD, BA, FACP</i> <i>Christian Thiede, MD</i>
3:20pm-3:50pm	Incorporating AML targeted therapy after allo-BMT in acute myelogenous leukemia <i>Speaker: Premal Lulla, MD</i> <i>Baylor College of Medicine, Cell and Gene therapy</i>
3:50pm-4:00pm	Closing remarks - abstract winners' announcement